BioArctic AB Class B (DE:B9A)
FRANKFURT:B9A
B9A Stock Chart & Stats
€28.52
-€0.37(-2.00%)
At close: 4:00 PM EST
€28.52
-€0.37(-2.00%)
Day’s Range― - ―
52-Week Range€14.83 - €34.96
Previous CloseN/A
Volume0.00
Average Volume (3M)292.00
Market Cap
€2.68B
Enterprise Value€28.47B
Total Cash (Recent Filing)€2.19B
Total Debt (Recent Filing)€72.42M
Price to Earnings (P/E)26.9
Beta0.52
Next Earnings
May 20, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding74,319,490
10 Day Avg. Volume102
30 Day Avg. Volume292
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)13.99
Price to Sales (P/S)13.76
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.17
Revenue Forecast (FY)€112.00M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low reported leverage gives BioArctic durable financial flexibility: it reduces insolvency risk, supports funding of clinical programs without urgent external financing, and preserves option value for selective partnering or licensing over the next 2–6 months and beyond.
Partnering/licensing Business ModelA model focused on early R&D plus partnering for late-stage development and commercialization lowers BioArctic's capital intensity and operating leverage. Durable streams from upfronts, milestones and royalties let the company scale without building full commercial infrastructure.
2025 Profitability Inflection And High MarginsA sharp 2025 margin improvement points to scalable revenue recognition (low incremental cost) when milestones hit. If milestone-driven receipts persist, the high gross and net margins can sustain elevated returns and improve ROE and reinvestment capacity over the medium term.
Bears Say
Uncertain Free Cash Flow DurabilityZero reported FCF in 2025 despite operating cash rebound signals that after-investment cash available to shareholders or reinvestment is uncertain. The historical lumpy cash conversion makes funding cadence and capital allocation decisions less predictable over coming quarters.
Earnings Volatility And Milestone TimingRevenue and profit swings tied to milestone timing create lumpy performance and forecasting risk. This structural pattern reduces predictability of earnings and cashflow, complicating budgeting, partner negotiations and long-term reinvestment planning for management and investors.
Concentration Risk On Key PartnerHeavy dependence on a single major partner/product chain links BioArctic’s revenue to external clinical, regulatory and commercial outcomes. Partner decisions or weaker-than-expected product performance could materially affect revenue streams and reduce the company's control over commercialization outcomes.
BioArctic AB Class B News
B9A FAQ
What was BioArctic AB Class B’s price range in the past 12 months?
BioArctic AB Class B lowest stock price was €14.83 and its highest was €34.96 in the past 12 months.
What is BioArctic AB Class B’s market cap?
BioArctic AB Class B’s market cap is €2.68B.
When is BioArctic AB Class B’s upcoming earnings report date?
BioArctic AB Class B’s upcoming earnings report date is May 20, 2026 which is in 36 days.
How were BioArctic AB Class B’s earnings last quarter?
BioArctic AB Class B released its earnings results on Feb 18, 2026. The company reported -€0.009 earnings per share for the quarter, beating the consensus estimate of -€0.05 by €0.041.
Is BioArctic AB Class B overvalued?
According to Wall Street analysts BioArctic AB Class B’s price is currently Overvalued.
Does BioArctic AB Class B pay dividends?
BioArctic AB Class B does not currently pay dividends.
What is BioArctic AB Class B’s EPS estimate?
BioArctic AB Class B’s EPS estimate is -0.03.
How many shares outstanding does BioArctic AB Class B have?
BioArctic AB Class B has 74,319,490 shares outstanding.
What happened to BioArctic AB Class B’s price movement after its last earnings report?
BioArctic AB Class B reported an EPS of -€0.009 in its last earnings report, beating expectations of -€0.05. Following the earnings report the stock price went up 18.188%.
Which hedge fund is a major shareholder of BioArctic AB Class B?
Currently, no hedge funds are holding shares in DE:B9A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioArctic AB Class B
BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia and traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical Phase for patients with early Alzheimer's disease. It also develops ABBV-0805, a monoclonal antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase I/II clinical trial for spinal cord injuries. In addition, the company develops imaging and biochemical biomarkers for Alzheimer's and Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier, as well as focuses on developing ND3014 antibodies for treating neurodegenerative disorders; AD1801, AD1502, AD1503, AD-BT2802, AD-BT2803, and AD2603 for the treatment of Alzheimer's disease; and PD1601 and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.
Technical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
Vicore Pharma Holding AB
―
Xspray Pharma AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---